Zhuo, Chao
Zheng, Bo
Wattanakamolkul, Kittima
Nakayama, Yoshikazu
Cloutier, Martin
Gauthier-Loiselle, Marjolaine
Feng, Jun
Wu, David
Neary, Maureen P.
Geurtsen, Jeroen
El Khoury, Antoine C.
Gu, Yoshiaki
Funding for this research was provided by:
Janssen Global Services, LLC
Article History
Received: 29 September 2023
Accepted: 18 December 2023
First Online: 24 January 2024
Declarations
:
: Bo Zheng, Yoshiaki Gu, and Chao Zhuo have no conflicts of interest. Yoshikazu Nakayama and Kittima Wattanakamolkul are employees of Janssen Pharmaceutical K.K. Jun Feng and David Wu are employees of Johnson & Johnson International (Singapore) PTE. Ltd. Jeroen Geurtsen is an employee of Janssen Vaccines & Prevention BV and owns stock. Maureen P. Neary and Antoine C. El Khoury are employees of Janssen Global Services, LLC and own stock. Martin Cloutier and Marjolaine Gauthier-Loiselle are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Global LLC, which funded the development and conduct of this study and manuscript.
: This study complies with the ethical standards of the Helsinki Declaration. Data were de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) (ExternalRef removed).